Rekombinanter EGFR (Zalutumumab Biosimilar) Antikörper

Produktnummer ABIN7487724

Produktdetails anti-EGFR (Zalutumumab Biosimilar) Antikörper

Target: EGFR (Zalutumumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser EGFR (Zalutumumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA, Flow Cytometry (FACS), Western Blotting (WB)

Verwendungszweck: Anti-EGFR [2F8 (Zalutumumab, HuMax-EGFR)], Rabbit IgG, kappa

Spezifität: This antibody binds domain III of the human epidermal growth factor receptor (EGFR).

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.

Klon: 2F8

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: This antibody blocks the binding of EGF and TGF-α to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 μg/mL (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealsed that 2F8/HuMax-EGFR can be safely administered in doses upto 8 mg/kg (Bastholt et al., 2007) Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactice conformation. Biochemical analyses showed bivalent binding of 2F8 to provide potent inhibition of EGFR signaling (Beuren et al., 2008). EGFRvIII-specific CDC was significantly enhanced when zalutumumab was combined with a Fc-engineered variant of antibody MR1-1 (Klausz et al., 2011).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu EGFR (Zalutumumab Biosimilar)

Target: EGFR (Zalutumumab Biosimilar)

Abstract: EGFR (Zalutumumab Biosimilar) Produkte

Hintergrund: ERBB1, ERBB, Erb-B2, HER1, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1

UniProt: P00533